Celcuity is a clinical stage biotechnology company with a mission to discover previously undetectable cancer drivers and develop drugs to treat them. Our approach is centered around unraveling complex oncogenic activity through our third-generation cellular analysis platform. By harnessing unparalleled insights into oncogenic pathways, we aim to develop new targeted therapies for cancer patients.

Our lead candidate, gedatolisib, is a dual PI3K-mTOR inhibitor, specifically designed to disrupt the target pathway and inhibit the oncogenic process. Unlike traditional molecular tests, our platform provides comparative analyses of different drugs using live patient tumor cells. This reveals unique opportunities to develop first-in-class drugs and create new potential applications for targeted therapies.

We are committed to providing options and delivering hope to cancer patients by bringing revolutionary treatments to the market. Stay updated on our latest news and developments, including our Phase 1b/2 clinical trials and collaborations with leading organizations such as Bayer. Celcuity is headquartered in Minneapolis, Minnesota, and we are dedicated to driving innovation in the fight against cancer